Quantcast

Industry news that matters to you.  Learn more

Launch of Consumer Health Intelligence Service Onegevity Combines Blood, Genome and Microbiome Analysis for Personalized Health and Wellness

January 15 marks the official launch of Onegevity Health as a new consumer health intelligence company, which combines a multi-omic artificial intelligence (AI) platform with consumer-friendly products and digital services. Onegevity will provide a comprehensive molecular portrait and customized recommendations for an individual’s health based on integrated analysis of longitudinal blood, genetics, and gut microbiome profiles.

Collaboration at Eskenazi Health Explores Ways to Personalize Medicine

In cooperation with Eskenazi Health, the Indiana Institute for Personalized Medicine, the Indiana University School of Medicine and the Regenstrief Institute are evaluating how genetics impact the responsiveness and efficacy of certain drugs. It is believed to be the first study of its kind to examine both the economic and clinical value of implementing personalized medicine.

Parkinson’s Biomarker Initiative Expands Study of Genetics

The Parkinson’s Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson’s disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants — people with or at risk to develop Parkinson’s — will lead to therapeutics that would help all Parkinson’s patients and ultimately provide strategies to prevent disease onset.

Regeneron Launches New Human Genetics Initiative

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently announced that it has launched a new human genetics initiative via a new wholly owned subsidiary, the Regeneron Genetics Center LLC (RGC). The objective of the RGC is to expand the use of human genetics for defining disease targets and improving the drug development process. The RGC will pursue both large population-based efforts as well as family-based approaches.

Multiplicom Launches Three New Mutation Detection Kits to Enable the Implementation of Personalized Cancer Treatment

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), recently announced that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level.